| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Ironwood Pharmaceuticals, Inc.$4.47
-0.18 (-3.85%)
B 60Pipeline Score Fair Value Pharma · Commercial
Market Cap
645.28 M
EPS
0.63
P/E Ratio
6.56 $
Value Trade
8.66 M
SEC Financials
Q1 2026Dilution Risk
Revenue
106.51 M
R&D Expenses
21.94 M
Operating CF
5.12 M
Total Assets
434.57 M
Total Liabilities
434.57 M
Equity
-217.14 M
D/E Ratio
12,345
9.5 %
Week
-4.39 %
1 Month
-13.85 %
3 Month
22.5 %
6 Month
-68.64 %
5 Year
-62.25 %
All Time
Cash Data
Cash Position
220.47 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
2.77 M
52 Week Range
0.56 - 5.78
% held by Insiders
3.72 %
% held by Institutions
98.46 %
Enterprise Value
1.02 B
Total Shares
164.58 M
Short %
10.03 %
Float Shares
149.44 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ironwood Pharmaceuticals, Inc.
380Total events
1Upcoming
136Tier-1 (high impact)
2014 – 2026Coverage
Upcoming catalysts 1
Event history 379
Q2 2026
◆Trial InitiationapraglutideTrial
Initiate confirmatory Phase 3 trial of apraglutide for SBS-IF
short bowel syndrome with intestinal failure (SBS-IF)source ↗
Jun 4, 2026
◆Oral PresentationPresentation
Ironwood Pharmaceuticals to participate in Jefferies Global Healthcare Conference fireside chat
Jun 1, 2026
◆Oral PresentationPresentation
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 27, 2026
▲FDA ApprovalLINZESSApprovedFDA Decision
FDA approves LINZESS for pediatric FC patients aged 2+
functional constipation (FC) in pediatric patients two years of age and oldersource ↗
May 24, 2026
◆PDUFA DateLINZESSApprovedRegulatory Filing
PDUFA date of May 24, 2026 for LINZESS sNDA for FC in patients 2-5 years
functional constipation (FC) in patients 2 to 5 years of agesource ↗
May 7, 2026
▲Quarterly UpdateCorporate
Ironwood reports Q1 2026 financial results and maintains full-year 2026 guidance
May 7, 2026
▲FDA Filing AcceptedLINZESSApprovedRegulatory Filing
sNDA for LINZESS in FC pediatric patients 2-5 years accepted and granted priority review by FDA
functional constipation (FC) in patients 2 to 5 years of agesource ↗
May 4, 2026
●Oral PresentationPresentation
Survey findings presented at DDW 2026
Short Bowel Syndrome (SBS)source ↗
May 2, 2026
◆Oral PresentationPresentation
Presentation of LANDMARK survey data on HCP perspectives on TPN burden in SBS at DDW 2026
Short Bowel Syndrome (SBS)source ↗
May 2026
▲Oral PresentationapraglutidePresentation
Pooled data from STARS program presented at DDW 2026
short bowel syndrome with intestinal failure (SBS-IF)source ↗
Q2 2026
◆Trial InitiationapraglutideTrial
Site initiation for confirmatory Phase 3 STARS-2 trial of apraglutide in SBS-IF
short bowel syndrome with intestinal failure (SBS-IF)source ↗
Q1 2026
◆Quarterly UpdateCorporate
Provide details on apraglutide trial design in Q4 and full-year 2025 update
Drug Pipeline Intelligence
B60
Pipeline Score $1.8B
Pipeline ValueFair Value
Valuation Signal12
Drugs Scored2.8x
rNPV / MCap Top 87%
Micro Cap (rank 119 of 911)
Percentile RankIronwood Pharmaceuticals, Inc. holds a solid B-grade pipeline (60/100), with $9.0B risk-adjusted pipeline value, led by IW-3718 in Gastroesophageal Reflux Disease (GERD) (Phase 3), across $194B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IW-3718 Small molecule | Gastroesophageal Reflux Disease (GERD) | Phase 3 | NCT03561883 | 49% | $2.4B | COMPLETED | 609 | - | - | Nov 6, 2020 | - | Aug 18, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
apraglutide | short bowel syndrome with intestinal failure | Phase 3 | 2024-05-09 | In the Phase III STARS trial, once-weekly apraglutide demonstrated significant efficacy in adults with short bowel syndrome, showing a positive response rate and validating its potential as the first GLP-2 analog for patients dependent on parenteral support. Read More | Ironwood Pharmaceuticals Reports First Quarter 2024 Results - Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SB Read More | |
apraglutide | short bowel syndrome with intestinal failure | Phase 3 | 2024-05-09 | In the Phase III STARS trial, once-weekly apraglutide demonstrated significant efficacy in adults with short bowel syndrome, showing a positive response rate and validating its potential as the first GLP-2 analog for patients dependent on parenteral support. Read More | Ironwood Pharmaceuticals Reports First Quarter 2024 Results - Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SB Read More | |
apraglutide | short bowel syndrome with intestinal failure | Phase 3 | 2024-05-09 | In the Phase III STARS trial, once-weekly apraglutide demonstrated significant efficacy in adults with short bowel syndrome, showing a positive response rate and validating its potential as the first GLP-2 analog for patients dependent on parenteral support. Read More | Ironwood Pharmaceuticals Reports First Quarter 2024 Results - Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SB Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IRWD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IRWD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IRWDIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2026
Ironwood Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 4, 2026, with a fireside chat scheduled for 11:05 a.m. ET. The event will be accessible via a live webcast on the company's website, with a replay available afterward. Ironwood is known for developing therapies for gastrointestinal and rare diseases.
Read more →IRWDIronwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Ironwood Pharmaceuticals is set to participate in the Jefferies Global Healthcare Conference. This event will provide a platform for the company to discuss its strategies and developments in the healthcare sector. Further details about the conference and Ironwood's agenda have not been disclosed.
Read more →IRWDFDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
The FDA has approved LINZESS® (linaclotide) for use in pediatric patients aged two years and older who suffer from functional constipation. This approval provides a new treatment option for a condition that can significantly impact children's quality of life. The decision reflects the growing recognition of the need for effective therapies in younger populations.
Read more →IRWD▼ -13.7%on this news
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
Ironwood Pharmaceuticals reported a strong first quarter for 2026, with total revenue reaching $106.5 million, a significant increase from $41.1 million in the same period last year. The company attributes this growth primarily to a 97% rise in LINZESS U.S. net sales, driven by improved pricing and prescription demand. Ironwood also remains on track to initiate the STARS-2 Phase 3 clinical trial for apraglutide, which aims to redefine treatment standards for short bowel syndrome.
Read more →IRWD▼ -13.7%on this news
Ironwood Pharmaceuticals Reports Strong First
Ironwood Pharmaceuticals has reported strong financial results for Q1 2026, highlighting a 97% year-over-year increase in U.S. net sales for LINZESS, totaling $273 million. The company's total revenue reached $107 million, indicating significant business performance. Notably, Ironwood is on track to initiate site operations for a Phase 3 trial of apraglutide in treating short bowel syndrome and has received FDA priority review for a supplemental NDA related to LINZESS for younger patients. Overall, Ironwood maintains confidence in its full-year financial guidance.
Read more →IRWDIronwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
Ironwood's survey findings presented at DDW 2026 highlight the complexities surrounding Total Parenteral Nutrition (TPN) in patients with Short Bowel Syndrome (SBS). The data emphasizes the necessity for therapies that can effectively address the multifaceted burdens associated with TPN. This underscores the ongoing challenges faced by patients and the need for innovative solutions in their treatment.
Read more →IRWDIronwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
Ironwood Pharmaceuticals has announced an investor update conference call scheduled for May 7, 2026. The call will provide insights into the company's developments and future plans. Participants can join via phone or webcast, with replays available shortly after the call. Ironwood continues to focus on innovative therapies for gastrointestinal and rare diseases.
Read more →IRWD▼ -9.3%on this news
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
Ironwood Pharmaceuticals will present findings from its LANDMARK survey at the 2026 Digestive Disease Week. The focus will be on healthcare professionals' perspectives regarding the burden of total parenteral nutrition in patients with short bowel syndrome. This presentation aims to shed light on critical insights that could influence treatment approaches.
Read more →IRWDIronwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Ironwood Pharmaceuticals will participate in The Citizens Life Sciences Conference, emphasizing its commitment to advancing gastrointestinal healthcare. The company's mission is to redefine the standard of care for patients suffering from GI diseases. This participation showcases Ironwood's role in the healthcare landscape.
Read more →IRWD▲ +8.9%on this news
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
Ironwood Pharmaceuticals reported strong financial results for 2025, achieving $296 million in revenue and a GAAP net income of $24 million. The company expects continued growth for LINZESS and has finalized the design for a Phase 3 clinical trial of apraglutide in short bowel syndrome. Ironwood is well-positioned for 2026 with a projected adjusted EBITDA exceeding $300 million.
Read more →IRWD▼ -11.3%on this newsshared move
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook - LINZESS (linaclotide) EUTRx demand growth of 11% for
Ironwood Pharmaceuticals has reported its fourth quarter and full-year results for 2025, achieving a revenue of $296 million and a GAAP net income of $24 million. The company experienced an 11% growth in EUTRx demand for LINZESS, cementing its market leader position. Looking ahead, Ironwood estimates U.S. LINZESS net sales for 2026 to be between $1.125 to $1.175 billion and plans to initiate a Phase 3 clinical trial for apraglutide in short bowel syndrome in the second quarter of 2026. Additionally, the company's strong cash position supports its future growth strategies.
Read more →IRWDIronwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
Ironwood Pharmaceuticals has announced it will host an investor update call for the fourth quarter and full year of 2025. This call aims to provide shareholders with insights into the company's financial performance and strategic direction. The event underscores Ironwood's commitment to maintaining open communication with its investors.
Read more →IRWD▲ +7.5%on this news
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
Ironwood Pharmaceuticals has announced its financial guidance for FY 2026, projecting U.S. net sales of LINZESS between $1.125 to $1.175 billion and total revenues of $450 to $475 million. The company ended Q4 2025 with over $200 million in cash and plans to initiate a confirmatory Phase 3 trial for apraglutide in the first half of 2026. CEO Tom McCourt emphasized the focus on maximizing LINZESS and advancing apraglutide while maintaining financial stability.
Read more →IRWD▲ +26.7%on this newsshared move
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance - Expects full-year 2026 LINZESS U.S. net sales of $1.125 to $1.175 billion; total revenues of
Ironwood Pharmaceuticals announced its financial guidance for FY 2026, projecting LINZESS U.S. net sales between $1.125 to $1.175 billion and total revenues of $450 to $475 million. The company is focused on maximizing LINZESS while also advancing apraglutide for short bowel syndrome. Ironwood aims to deliver over $300 million in adjusted EBITDA in 2026, benefiting from a scheduled reduction in LINZESS's list price. The company reported cash reserves exceeding $200 million, positioning itself for continued growth and shareholder value in the upcoming year.
Read more →IRWD▲ +31.8%on this news· ran to +76% by day 3
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance - LINZESS (Iinaclotide) U.S. net sales of $315 million in Q3 2025, an increase of 40% yea
Ironwood Pharmaceuticals announced strong results for the third quarter of 2025, achieving U.S. net sales of $315 million for LINZESS, a 40% increase from the previous year. The company has raised its full-year financial guidance, expecting LINZESS sales to reach between $860 million and $890 million. Additionally, the FDA has approved LINZESS for treating IBS-C in children aged 7 and older, further expanding its market reach. Ironwood anticipates significant cash flows in the fourth quarter to strengthen its financial position and reduce debt.
Read more →IRWD▲ +31.8%on this news· ran to +76% by day 3
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
Ironwood Pharmaceuticals has announced strong financial results for the third quarter of 2025, demonstrating significant growth. The company has also raised its financial guidance for the full year 2025, indicating confidence in its future performance. This positive outlook reflects the company's successful strategies and market position.
Read more →IRWD▲ +9.3%on this news· ran to +22% by day 3
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance - LINZESS (Iinaclotide) U.S. net sales of $248 million in Q2 2025; EUTRx demand growth of 10
Ironwood Pharmaceuticals has announced its second quarter 2025 results, highlighting U.S. net sales of $248 million for LINZESS and a 10% growth in EUTRx demand year-over-year. The company reiterated its confidence in achieving its financial guidance for the full year 2025. Additionally, Ironwood plans to align with the FDA on the confirmatory Phase 3 trial design for apraglutide in Q4 2025. The strategic review process aimed at increasing shareholder value is also ongoing.
Read more →IRWD▲ +9.3%on this news· ran to +22% by day 3
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
Ironwood Pharmaceuticals announced its second quarter results for 2025, showcasing strong financial performance. The company has reaffirmed its financial guidance for the entire year, indicating stability and confidence in its operations. This announcement signals a positive trajectory for Ironwood as it navigates the current market landscape.
Read more →IRWD▼ -14.6%on this news
Ironwood Pharmaceuticals Reports First Quarter 2025 Results - On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 - - LINZESS (Iinac
Ironwood Pharmaceuticals announced its first-quarter 2025 results, reporting continued strong demand for its LINZESS product, which saw an 8% growth compared to the previous year. The company has raised its adjusted EBITDA guidance to over $105 million for 2025. However, total revenue has dropped significantly compared to the same period last year, leading to a larger GAAP net loss. Ironwood is actively exploring strategic alternatives to enhance shareholder value amid these financial shifts.
Read more →IRWD▼ -14.6%on this news
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
Ironwood Pharmaceuticals has released its financial results for the first quarter of 2025. The report includes various aspects of the company's operations, including leadership, therapeutic focus, and pipeline developments. However, specific financial figures and performance metrics were not detailed in the provided text.
Read more →IRWDIronwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and t
Ironwood Pharmaceuticals has reiterated its guidance for LINZESS U.S. net sales, expecting them to be between $800-$850 million for 2025. The company has raised its adjusted EBITDA guidance to over $105 million, reflecting operational changes and shifts in focus towards confirmatory trials. Despite a strong prescription demand growth of 8% year-over-year, Ironwood is wary of pricing pressures related to changes in Medicare policies. The financial results for the first quarter of 2025 are expected to be reported in early May.
Read more →IRWDIronwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
Ironwood Pharmaceuticals has reaffirmed its full-year 2025 net sales guidance for LINZESS in the U.S. Additionally, the company has raised its adjusted EBITDA guidance, suggesting an optimistic financial outlook. This announcement reflects the company's confidence in the continued performance of LINZESS in the market.
Read more →IRWDIronwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
Ironwood Pharmaceuticals will present real-world data at Digestive Disease Week 2025. The focus will be on the adoption of new diagnosis codes for short bowel syndrome patients reliant on parenteral support. This presentation aims to improve patient care and understanding of the condition.
Read more →IRWD▼ -31.5%on this news
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
Ironwood Pharmaceuticals has provided a clinical and regulatory update regarding Apraglutide, a treatment aimed at gastrointestinal diseases. The company emphasizes its commitment to improving care standards for GI patients. This announcement highlights the progress being made in the development of Apraglutide.
Read more →IRWD▼ -31.5%on this news
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide - Feedback from recent FDA interaction indicates that a confirmatory Phase 3 trial evaluating apraglutide in SBS-IF is
Ironwood Pharmaceuticals announced a regulatory update on its drug apraglutide, revealing a need for a confirmatory Phase 3 trial as per recent feedback from the FDA to seek approval for short bowel syndrome patients dependent on parenteral support. The company expressed disappointment over this requirement but remains committed to advancing the drug and plans to collaborate with the FDA on trial design. Additionally, Ironwood has engaged Goldman Sachs to explore strategic alternatives aimed at maximizing stockholder value.
Read more →IRWDIronwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
Ironwood Pharmaceuticals has received a notification from Nasdaq for non-compliance due to a delay in filing its 2024 Form 10-K. This notification is a standard procedure and does not have an immediate effect on the company's stock listing. Ironwood has 60 days to submit a plan to regain compliance, as they expect to file the report soon. Concerns about financial transparency may arise with this delayed filing.
Read more →IRWD▼ -5.3%on this news
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
Ironwood Pharmaceuticals has announced its financial results for the fourth quarter and full year of 2024. The company successfully met its financial guidance for the year, indicating strong performance. This achievement reflects positively on Ironwood's operational strategies and market position.
Read more →IRWD▼ -5.3%on this news
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance - Announced positive data from open-label extension study demonstrating an increased numb
Ironwood Pharmaceuticals reported its fourth quarter and full year 2024 results, achieving a total revenue of $351 million and stable net income of $2 million. The company highlighted significant progress in the clinical development of apraglutide, with promising data from an open-label study showcasing increased patient benefit over time. Looking ahead, Ironwood is advancing its rolling NDA submission for apraglutide, aiming for completion by Q3 2025. The company also noted a year-over-year growth in prescription demand for its Iinaclotide product, though overall total revenue declined compared to the previous year.
Read more →IRWDIronwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
Ironwood Pharmaceuticals has announced it will host an investor update call for the fourth quarter and full year of 2024. This event aims to provide insights into the company's financial performance and strategic direction. The call reflects Ironwood's commitment to maintaining open lines of communication with its investors.
Read more →IRWDIronwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
Ironwood Pharmaceuticals has initiated the NDA submission for Apraglutide, presenting new compelling data that supports its efficacy. The company has also updated its corporate structure to better position itself for future growth. This move indicates a strategic focus on advancing its pipeline and enhancing shareholder value.
Read more →IRWD▲ +5.1%on this news
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
Ironwood Pharmaceuticals is set to participate in the Piper Sandler 36th Annual Healthcare Conference. This engagement highlights the company's commitment to sharing its advancements and fostering connections within the healthcare community. The conference serves as a significant opportunity for Ironwood to present its initiatives to potential investors and stakeholders.
Read more →IRWDIronwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
Ironwood Pharmaceuticals announced its participation in the Jefferies London Healthcare Conference scheduled for November 2024. This event is significant for the company as it allows them to present their latest advancements and engage with investors. The conference is a key platform for networking and showcasing innovations in the healthcare sector.
Read more →IRWD▼ -7.5%on this news
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results - LINZESS (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year - - Remains on track to complete apraglutide NDA submission
Ironwood Pharmaceuticals reported a significant 13% year-over-year growth in prescription demand for LINZESS in its third quarter results for 2024. Despite facing pricing challenges, the company is maintaining its full-year financial guidance and is on track to submit its NDA for apraglutide in Q1 2025, which aims to address short bowel syndrome. However, total revenue for the quarter was lower compared to the previous year, emphasizing some financial pressures.
Read more →IRWD▼ -7.5%on this news
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
Ironwood Pharmaceuticals has released its financial results for the third quarter of 2024. The report includes various aspects of the company's operations, including leadership, therapeutic focus, and pipeline updates. However, specific financial figures and performance metrics were not detailed in the provided text.
Read more →IRWDOnce-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
Ironwood Pharmaceuticals presented new Phase III data on apraglutide for treating adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) at ACG 2024. The results showed a consistent treatment effect across different baseline demographics and disease characteristics. This data highlights the potential of apraglutide as a viable treatment option for patients suffering from SBS-IF.
Read more →IRWDIronwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
Ironwood Pharmaceuticals has announced it will host an investor update call for the third quarter of 2024. The company, known for its focus on gastrointestinal healthcare, aims to enhance treatment options and improve care standards for patients. This call represents an opportunity for investors to gain insights into the company's progress and future plans.
Read more →IRWD▲ +7.6%on this news
Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
Ironwood Pharmaceuticals has announced its participation in the 2024 Wells Fargo Healthcare Conference. This event is significant for the company as it provides an opportunity to engage with investors and industry stakeholders. The conference is expected to enhance Ironwood's visibility in the healthcare sector.
Read more →IRWD▼ -32.6%on this news
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
Ironwood Pharmaceuticals has released its financial results for the second quarter of 2024. The report includes various aspects of the company's operations, including leadership, pipeline, and therapeutic focus. However, specific financial figures and performance metrics are not detailed in the provided text.
Read more →IRWD▼ -32.6%on this news
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results - LINZESS (Iinaclotide) EUTRx prescription demand growth of 11% year-over-year - - Plans to pursue apraglutide rolling NDA review; expect
Ironwood Pharmaceuticals reported its second-quarter results for 2024, highlighting an 11% increase in LINZESS prescription demand compared to the previous year. The company plans to pursue a rolling NDA review for apraglutide, expecting to complete submission in early 2025. Despite the positive demand growth, Ironwood is facing pricing pressure on LINZESS due to increased Medicaid utilization, leading to revised financial guidance suggesting a decline in net sales. The company remains optimistic about cash flow generation from LINZESS and the clinical prospects for apraglutide.
Read more →IRWDIronwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
Ironwood Pharmaceuticals has announced it will host an investor update call for the second quarter of 2024. This call aims to provide insights into the company's performance and future plans. The event reflects Ironwood's commitment to maintaining transparency and open communication with its stakeholders.
Read more →IRWD▲ +5.6%on this news
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Ironwood Pharmaceuticals presented a late-breaker session at Digestive Disease Week, emphasizing the potential benefits of once-weekly apraglutide for adults suffering from Short Bowel Syndrome with Intestinal Failure. The presentation aims to address the significant unmet medical needs within this patient demographic. The findings suggest promising outcomes that could enhance treatment options.
Read more →IRWD▼ -17%on this news
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
Ironwood Pharmaceuticals has reported its financial results for the first quarter of 2024. The report includes various aspects of the company's performance and operations. However, specific details regarding revenue, expenses, or strategic initiatives were not highlighted in the provided text.
Read more →IRWD▼ -17%on this news
Ironwood Pharmaceuticals Reports First Quarter 2024 Results - Reported positive topline results from global Phase III STARS trial of once-weekly apraglutide in adults with short bowel syndrome with intestinal failure (SB
Ironwood Pharmaceuticals announced its first quarter 2024 results highlighting positive topline results from the Phase III STARS trial of apraglutide, a GLP-2 analog for patients with short bowel syndrome. The company reported a substantial year-over-year increase in LINZESS prescriptions, but revised its financial guidance downwards due to anticipated declines in net sales. CEO Tom McCourt expressed optimism about apraglutide's market potential and committed to filing an NDA soon. However, both total revenue and net income showed a decrease compared to the previous year.
Read more →IRWDIronwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
Ironwood Pharmaceuticals has announced its participation in The Citizens JMP Life Sciences Conference. The company focuses on advancing treatments for gastrointestinal diseases and aims to set new standards of care for patients. This involvement underscores Ironwood's commitment to innovation in the healthcare sector.
Read more →IRWD▲ +6.1%on this newsshared move
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
Ironwood Pharmaceuticals announced that it will present new data on its once-weekly apraglutide treatment for Short Bowel Syndrome with Intestinal Failure at the upcoming Digestive Disease Week 2024. This presentation highlights the company's commitment to addressing this challenging condition. The event is anticipated to draw significant attention within the medical community.
Read more →IRWDIronwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
Ironwood Pharmaceuticals has announced it will host an investor update call for the first quarter of 2024. This call aims to provide insights into the company's performance and future outlook. The event reflects the company's commitment to transparency and investor engagement.
Read more →IRWDIronwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
Ironwood Pharmaceuticals has announced positive outcomes from its Phase II STARGAZE trial, which evaluated apraglutide in patients suffering from steroid-refractory gastrointestinal acute graft-versus-host disease (SR GI aGVHD). The results indicate that apraglutide may be an effective treatment option for this challenging condition. This development could significantly impact patient care and treatment strategies in this area.
Read more →IRWD▼ -37.6%on this news
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Ironwood Pharmaceuticals has announced positive topline results from its global Phase III trial of apraglutide, a once-weekly treatment for adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF). The trial's success suggests that apraglutide may significantly benefit patients suffering from this condition. The findings could lead to improved treatment options and patient outcomes.
Read more →IRWDIronwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
Ironwood Pharmaceuticals announced its participation in the ASPEN 2024 Nutrition Science & Practice Conference, where it will present four abstracts. This involvement underscores the company's dedication to advancing research in nutrition science. The conference serves as a significant platform for sharing innovative findings in the field.
Read more →IRWDIronwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
Ironwood Pharmaceuticals reported its fourth quarter and full year 2023 results, successfully achieving its financial guidance for the year. The company highlighted strong performance metrics in its latest earnings report, indicating a positive trajectory moving forward. This achievement reflects Ironwood's strategic initiatives and operational effectiveness.
Read more →IRWDIronwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance - LINZESS (Iinaclotide) 2023 U.S. net sales of $1.1 billion, an increase of 7% year-over-
Ironwood Pharmaceuticals reported its fourth quarter and full year 2023 results, highlighting a 7% increase in LINZESS net sales to $1.1 billion. The company achieved revenue of $443 million with strong prescription demand for LINZESS, especially following its FDA approval for pediatric use. Ironwood anticipates continued growth with upcoming topline data from the STARS Phase III study of apraglutide for short bowel syndrome expected in March 2024, despite facing significant operating losses for the year.
Read more →IRWDIronwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
Ironwood Pharmaceuticals has announced an upcoming investor update call scheduled for the fourth quarter and full year of 2023. This call aims to provide stakeholders with insights into the company's performance and future outlook. The event reflects Ironwood's commitment to maintaining open communication with its investors.
Read more →IRWDIronwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
Ironwood Pharmaceuticals has announced the publication of new Phase III data for linaclotide, targeting children and adolescents aged 6-17 years with functional constipation. The study was published in The Lancet Gastroenterology & Hepatology, highlighting the efficacy and safety of linaclotide in this age group. This development could enhance treatment options for pediatric patients.
Read more →IRWDIronwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
Ironwood Pharmaceuticals has confirmed its financial guidance for the fiscal year 2023 while also announcing its financial guidance for fiscal year 2024. This move reflects the company's confidence in its ongoing operations and future prospects. The announcement was made on January 8, 2024, highlighting the company's strategic planning.
Read more →IRWDIronwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance - Expects high-single digit percentage LINZESS EUTRx prescription demand growth in 2024 - - Exp
Ironwood Pharmaceuticals has maintained its financial guidance for FY 2023 and announced FY 2024 predictions, indicating high-single digit growth in LINZESS demand. The company expects over $150 million in adjusted EBITDA, reflecting its strong market position and growth potential in its GI development pipeline. Despite projections for continued growth, the company also acknowledges potential price erosion caused by Medicaid policies. The upcoming J.P. Morgan Healthcare Conference presentation is set for January 10, 2024, where more insights may be shared.
Read more →IRWDIronwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Ironwood Pharmaceuticals is set to present at the 42nd Annual J.P. Morgan Healthcare Conference. This event is a significant platform for companies in the healthcare sector to showcase their innovations and strategies. The conference is expected to enhance Ironwood's visibility among investors and industry stakeholders.
Read more →IRWDIronwood Announces the Completion of Squeeze-Out Merger With VectivBio
Ironwood Pharmaceuticals has announced the successful completion of its squeeze-out merger with VectivBio. This merger is expected to enhance Ironwood's capabilities and product offerings in the biopharmaceutical market. The strategic integration aims to leverage VectivBio's assets and expertise to further strengthen Ironwood's position.
Read more →IRWDIronwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference
Ironwood Pharmaceuticals announced its participation in the Piper Sandler 35th Annual Healthcare Conference. This event represents an opportunity for the company to engage with investors and discuss its strategic direction. The conference is a notable event in the healthcare sector, attracting significant attention from industry stakeholders.
Read more →IRWDIronwood Pharmaceuticals Reports Third Quarter 2023 Results
Ironwood Pharmaceuticals has released its third quarter results for 2023. The report includes various aspects of the company's operations, including leadership, therapeutic focus, and pipeline products. However, specific financial figures and performance metrics were not detailed in the provided text.
Read more →IRWDIronwood Pharmaceuticals Reports Third Quarter 2023 Results - LINZESS (Iinaclotide) EUTRx prescription demand growth increased 8% year-over-year; LINZESS U.S. net sales of $279 million, an increase
Ironwood Pharmaceuticals reported strong third quarter results for 2023, with LINZESS net sales increasing to $279 million and a year-over-year prescription demand growth of 8%. The company highlighted positive results from the STARS Nutrition study for apraglutide, further enhancing its portfolio. Despite the increase in operating expenses and a decrease in GAAP net income, Ironwood maintains its financial guidance for the year, indicating confidence in its pipeline and growth strategy as it aims to solidify its leading position in gastrointestinal healthcare.
Read more →IRWDIronwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
Ironwood Pharmaceuticals has announced it will host an investor update call for the third quarter of 2023. The company focuses on advancing treatments for gastrointestinal diseases and aims to set new standards in GI patient care. This call is part of their commitment to transparency with investors.
Read more →IRWDIronwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
Ironwood Pharmaceuticals announced the release of new data regarding Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC) at the American College of Gastroenterology 2023 Annual Scientific Meeting. This presentation highlights the company's ongoing research and commitment to improving treatment options for patients suffering from these conditions.
Read more →IRWDIronwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
Ironwood Pharmaceuticals has announced positive final data from its Phase II STARS Nutrition study, which evaluated Apraglutide for Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC). The results were presented at the United European Gastroenterology Week, highlighting the drug's potential efficacy in this patient population. This marks a significant advancement in treatment options for SBS-IF.
Read more →IRWDIronwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
Ironwood Pharmaceuticals announced that it will present new data at the NASPGHAN Annual Meeting. The data highlights the impact of Linaclotide on treating functional constipation in children and adolescents aged 6 to 17 years. This presentation aims to reinforce the drug's effectiveness in this demographic.
Read more →IRWD▼ -9.2%on this news
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS U.S. Net Sales and Ironwood Revenue Guidance - LINZESS (Iinaclotide) EUTRx prescription demand growth incr
Ironwood Pharmaceuticals reported second quarter 2023 results showcasing a 9% growth in LINZESS U.S. net sales, reaching $270 million. The company raised its full-year revenue guidance amidst expanding clinical applications for LINZESS, including a recent FDA approval to treat pediatric patients with functional constipation. Additionally, Ironwood's acquisition of VectivBio is set to enhance its gastrointestinal portfolio and pipeline, despite showing a substantial GAAP net loss primarily linked to this acquisition. The company's progress positions it well for future growth in the GI sector.
Read more →IRWD▼ -9.2%on this news
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
Ironwood Pharmaceuticals announced its second quarter 2023 financial results, highlighting an increase in its full-year guidance for LINZESS U.S. net sales. The report indicates strong performance in the second quarter, contributing to a positive outlook for the company's revenue. This guidance adjustment reflects confidence in LINZESS's market performance.
Read more →IRWDIronwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
Ironwood Pharmaceuticals has announced that it will host an investor update call for the second quarter of 2023. This call aims to provide insights into the company's performance and future plans. Such updates are crucial for maintaining investor relations and transparency in the biopharma sector.
Read more →IRWDIronwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares BOSTON and
Ironwood Pharmaceuticals has completed its tender offer for VectivBio, acquiring approximately 97.60 percent of its shares at $17.00 each. Following the acquisition, VectivBio's current directors were replaced by those appointed by Ironwood. The company plans to delist VectivBio's shares from Nasdaq and pursue a squeeze-out merger under Swiss law. While the acquisition is viewed positively, potential risks include integration challenges and uncertainties regarding future transactions.
Read more →IRWDEXECUTION VERSION PRIVILEGED AND CONFIDENTIAL FORM OF TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this " Agreement "), dated as of
Ironwood Pharmaceuticals has entered into a Tender and Support Agreement as of May 21, 2023, related to a cash tender offer for VectivBio Holding AG. The agreement outlines the terms under which stockholders will tender their shares. It has received unanimous approval from the Company Board, signaling a coordinated effort to proceed with the buyout plan. This transaction is conditioned on acquiring at least 90% of the outstanding shares of VectivBio.
Read more →IRWDIronwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance - LINZESS (Iinaclotide) EUTRx prescription demand growth increased 10% year- over-year; LINZE
Ironwood Pharmaceuticals reported its first quarter 2023 results, showing a 10% year-over-year increase in LINZESS prescription demand and achieving net sales of $250 million, an 8% rise from the previous year. The company also reported a GAAP net income of $46 million and an adjusted EBITDA of $60 million. With a robust cash reserve of $740 million, Ironwood remains focused on its pipeline and anticipates a potential pediatric indication for LINZESS in June. The company maintains its financial guidance for 2023, projecting net sales growth of 3% to 5%.
Read more →IRWDIronwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results - 2022 GAAP and non-GAAP net income of $175 million - - 2022 adjusted EBITDA of $252 million; ended 2022 with $656 million
Ironwood Pharmaceuticals reported their fourth quarter and full year 2022 financial results, achieving a GAAP and non-GAAP net income of $175 million. The company ended the year with $656 million in cash and cash equivalents and recorded an adjusted EBITDA of $252 million. Despite lower than anticipated sales growth for LINZESS due to inventory issues, Ironwood expressed optimism about strong prescription demand and plans for future growth, including a priority review from the FDA for a pediatric indication of LINZESS. The company aims to leverage their strong balance sheet to expand their gastrointestinal disease portfolio in 2023.
Read more →IRWD▼ -11%on this news
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance - sNDA submitted to U.S. FDA in December 2022 seeking approval of a new indication of
Ironwood Pharmaceuticals has updated its financial guidance for 2022 and announced its projections for 2023, showing optimistic growth potential driven by LINZESS demand. The company is preparing for submission to the U.S. FDA for a new indication of LINZESS in treating functional constipation in children and adolescents. Despite a slight revision for 2022 net sales, Ironwood expects significant demand growth and high adjusted EBITDA for 2023, which indicates a positive outlook for future strategic priorities. The presentation of this guidance precedes the upcoming J.P. Morgan Healthcare Conference.
Read more →IRWDIronwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance - LINZESS (Iinaclotide) EUTRx prescription demand growth in Q3 2022 increased 10% year
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance - LINZESS (Iinaclotide) EUTRx prescription demand growth in Q3 2022 increased 10% year-over-year - - Ironwood and its partner, AbbVie, plan to submit a supplementa
Read more →IRWDIronwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS Prescription Demand - LINZESS (Iinaclotide) EUTRx prescription demand
Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS LINZESS (Iinaclotide) EUTRx prescription demand growth in Q2 2022 increased 9% year-over-year - GAAP net income of $37 million and adjusted EBITDA of $56 milli
Read more →IRWDIronwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance - LINZESS (Iinaclotide) prescription demand growth increased 11% year-over-year; LINZESS U.S.
Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance LINZESS (Iinaclotide) prescription demand growth increased 11% year-over-year; LINZESS U.S. net sales of $232 million, an increase of 8% year-over-year - revenue of $98 million; U.S
Read more →IRWDIronwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021 - 2021 total revenue of $414
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 - 2021 total revenue of $414 million, driven primarily by $400 million in U.S. LINZESS collaboration revenue - - 2021 GAA
Read more →IRWDIronwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance - LINZESS Expected to Achieve Blockbuster Status with U.S. Net Sales in Excess of $1 B
Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance LINZESS Expected to Achieve Blockbuster Status with U.S. Net Sales in Excess of $1 Billion in 2021 - - Initiates Board Authorized Share Repurchase Program in Q4 202
Read more →IRWDIronwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update - LINZESS (Iinaclotide) prescription demand growth increased 12% year-over-year; LINZESS U.S. ne
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update LINZESS (Iinaclotide) prescription demand growth increased 12% year-over-year; LINZESS U.S. net sales of $253 million, an increase of 5% year-over-year - revenue of $104 mil
Read more →IRWDIronwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance - LINZESS (Iinaclotide) U.S. net sales of $259 million, an increase of 18% year-over-year - - Total rev
Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance - LINZESS (Iinaclotide) U.S. net sales of $259 million, an increase of 18% year-over-year - of $104 million, an increase of 16% year-over-year, driven primarily by U.S. LINZESS co
Read more →IRWDIronwood Pharmaceuticals Reports First Quarter 2021 Results - LINZESS (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year - -Total revenue of $89 million, an increase of
Pharmaceuticals Reports First Quarter 2021 Results LINZESS (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year - revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million - GAA
Read more →IRWDIronwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance - LINZESS (linaclotide)
Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance LINZESS (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LIN
Read more →IRWDThis presentation contains forward - looking statements . Investors are cautioned not to place undue reliance on these forward - looking statements, including statements about our ability to execute on our vision to beco
J.P. Morgan Healthcare Conference January 11, 2021 Exhibit 99.1 Ironwood: Leading in GI through Growth and Innovation To Become the Leading U.S. Gastrointestinal Healthcare Company 4 To advance the treatment of GI diseases and redefine the standard of care for GI patients OUR V
Read more →IRWDIronwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors
Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors Mass., December 3, 2020 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also serve as a m
Read more →IRWDIronwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance - U.S. LINZESS (linaclotide) net sales increased 10% year-over-year to $241 million
Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance U.S. LINZESS (linaclotide) net sales increased 10% year-over-year to $241 million, as reported by AbbVie Inc. (AbbVie) - U.S. LINZESS collaboration revenue to Ironwood in
Read more →IRWDIronwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million - Grew LINZESS (Iinaclotide) total prescription demand by 9%
Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net of $25 Million and Adjusted EBITDA of $33 Million Grew LINZESS (Iinaclotide) total prescription demand by 9% year-over-year; new-to-brand prescription demand grew >15% in June 2020 compared to March 2020 -
Read more →IRWDIronwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance -2019 revenue of $428 million, driven primarily
Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year revenue of $428 million, driven primarily by U.S. LINZESS (linaclotide) collaboration revenue- -GAAP net income from continuing operations of $59 mi
Read more →IRWDJ.P. Morgan 38 th Annual Healthcare Conference Ironwood Pharmaceuticals January 2020 2 Forward Looking Statements This presentation contains forward - looking statements. Investors are cautioned not to place undue relian
1 J.P. Morgan 38 th Annual Healthcare Conference Ironwood Pharmaceuticals January 2020 3 IRONWOOD'S VISION & MISSION Become the Leading U.S. Gastrointestinal Healthcare Company We are dedicated to advancing the treatment of GI diseases and redefining the standard of care for mil
Read more →IRWDIronwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance - - Total revenue of $131 million, driven primarily by LINZESS (linaclotide) U.S. collaboration revenue of
Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance - Total revenue of $131 million, driven primarily by LINZESS (linaclotide) U.S. collaboration revenue of $85 million and ex-U.S. license and milestone revenue of $42 million - $21 mill
Read more →IRWDIronwood Pharmaceuticals and AstraZeneca Amend LINZESS (linaclotide) Collaboration in China - Ironwood to receive up to $125 million, consisting of $35 million in non-contingent payments and up to $
Ironwood Pharmaceuticals and AstraZeneca LINZESS (linaclotide) Collaboration in China - Ironwood to receive up to $125 million, consisting of $35 million in non-contingent payments and up to $90 million in commercial milestones, in addition to tiered royalties up to 20 percen
Read more →IRWDIronwood Pharmaceuticals Reports Second Quarter 2019 Results Generated $12 million in GAAP net income from continuing operations and $26 million in adjusted EBITDA from continuing operations in 2Q 2
Ironwood Pharmaceuticals Reports Second Quarter 2019 Results Generated $12 million in GAAP net income from continuing operations and $26 million in adjusted EBITDA from continuing operations in 2Q 2019 Delivered second quarter 2019 revenue of $102 million, primarily driven by L
Read more →IRWDIronwood Pharmaceuticals to Establish New Headquarters in Downtown Boston New location designed to provide efficient and collaborative workspace and significant long-term cost savings
Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston New location designed to provide efficient and collaborative workspace and significant long-term cost savings CAMBRIDGE, Mass., June 13, 2019 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused h
Read more →IRWDEstimated Discontinued Operations 1Q 2019
Estimated Discontinued Operations 1Q 2019 May 14, 2019 Estimated Discontinued Operations Following the separation of Cyclerion Therapeutics, Inc. ( Cyclerion ), effective April 1, 2019, Ironwood Pharmaceuticals, Inc. ( Ironwood ) will present the effects of the disposition in di
Read more →IRWDIronwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance Ironwood launches as GI-focused healthcare company following
Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance Ironwood launches as GI-focused healthcare company following separation of Cyclerion Therapeutics on April 1, 2019 First quarter 2019 revenu
Read more →IRWDIronwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company Ironwood capitalizing on GI leadership and expertise in an effo
Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company Ironwood capitalizing on GI leadership and expertise in an effort to bring innovative therapies to patients Strategy centered on accelerating L
Read more →IRWDIronwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update Grew 2018 revenue 16% year-over-year to $347 million, driven primarily by U.S. LINZESS (linaclotide) collaboration
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update Grew 2018 revenue 16% year-over-year to $347 million, driven primarily by U.S. LINZESS (linaclotide) collaboration revenue of $264 million and linaclotide API sales of $70 million Progressed se
Read more →IRWDIronwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation Board members bring diverse experience tailored to the distinct opportunities and str
Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation Board members bring diverse experience tailored to the distinct opportunities and strategies of each new company Julie McHugh to serve as chair of Ironwood board;
Read more →IRWDJ.P. Morgan Healthcare Conference JANUARY 7 10, 2019 Forward looking statements This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statemen
J.P. Morgan Healthcare Conference JANUARY 7 10, 2019 Forward looking statements This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about expectations and timing rega
Read more →IRWDIronwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation Mark Mallon to become CEO of Ironwood Peter Hecht, founder and current
Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation Mark Mallon to become CEO of Ironwood Peter Hecht, founder and current CEO of Ironwood, to become CEO of Cyclerion (R&D Co.) Separation on track for
Read more →IRWDIronwood Pharmaceuticals Provides Third Quarter 2018 Investor Update LINZESS (linaclotide) U.S. net sales increased 7% to $205 million in 3Q 2018 vs 3Q 2017 Ironwood revenue of $66 million in 3Q 201
Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update LINZESS (linaclotide) U.S. net sales increased 7% to $205 million in 3Q 2018 vs 3Q 2017 Ironwood revenue of $66 million in 3Q 2018, which includes a $30 million reduction due to LINZESS change in estimate as
Read more →IRWDIronwood Pharmaceuticals Provides Second Quarter 2018 Investor Update Second quarter revenue increased 25% year-over-year to $81 million, driven primarily by LINZESS (linaclotide) U.S. net sales of
Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update Second quarter revenue increased 25% year-over-year to $81 million, driven primarily by LINZESS (linaclotide) U.S. net sales of $192 million and commercial margin of 60% Terminating licensing agreement with A
Read more →IRWDIronwood Pharmaceuticals Provides First Quarter 2018 Investor Update First quarter revenue increased 33% year-over-year to $69 million, driven primarily by LINZESS (linaclotide) U.S. net sales of $1
Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update First quarter revenue increased 33% year-over-year to $69 million, driven primarily by LINZESS (linaclotide) U.S. net sales of $159 million and commercial margin of 63% IW-3718 Phase III program expected to in
Read more →IRWDIronwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update Generated 2017 revenue of $298 million, driven primarily by LINZESS (linaclotide) U.S. net sales of $701 million a
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update Generated 2017 revenue of $298 million, driven primarily by LINZESS (linaclotide) U.S. net sales of $701 million and expansion of LINZESS commercial margin to 61% On track to advance key pipeli
Read more →IRWDIronwood Pharmaceuticals Strengthens Executive Leadership Team William Huyett Appointed to Chief Operating Officer Gina Consylman Promoted to Senior Vice President, Chief Financial Officer
Ironwood Pharmaceuticals Strengthens Executive Leadership Team William Huyett Appointed to Chief Operating Officer Gina Consylman Promoted to Senior Vice President, Chief Financial Officer CAMBRIDGE, Mass., November 28, 2017 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a com
Read more →IRWDIronwood Pharmaceuticals Provides Third Quarter 2017 Investor Update Ironwood revenue grew 31% to $87 million in 3Q 2017 over 3Q 2016 LINZESS (linaclotide) U.S. net sales increased 16% to $191 milli
Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update Ironwood revenue grew 31% to $87 million in 3Q 2017 over 3Q 2016 LINZESS (linaclotide) U.S. net sales increased 16% to $191 million and net profit increased 36% to $111 million in 3Q 2017 over 3Q 2016 Launch
Read more →IRWDIronwood Pharmaceuticals Announces Leadership Change
Ironwood Pharmaceuticals Announces Leadership Change CAMBRIDGE, Mass., September 6, 2017 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that Tom Graney, chief financial officer (CFO) and senior vice president, finance and corporate strategy will leave the company,
Read more →IRWDIronwood Pharmaceuticals Provides Second Quarter 2017 Investor Update LINZESS (linaclotide) expanded IBS-C/CIC branded prescription market leadership in 2Q 2017 with 19% growth in volume year-over-y
Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update LINZESS (linaclotide) expanded IBS-C/CIC branded prescription market leadership in 2Q 2017 with 19% growth in volume year-over-year and $168 million in U.S. net sales Positive IW-3718 Phase IIb top-line data
Read more →IRWDIronwood Pharmaceuticals Provides First Quarter 2017 Investor Update LINZESS (linaclotide) U.S. net sales grew to $148 million in 1Q 2017, primarily driven by more than 20% growth in LINZESS volume
Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update LINZESS (linaclotide) U.S. net sales grew to $148 million in 1Q 2017, primarily driven by more than 20% growth in LINZESS volume year-over-year Three LINZESS doses now available with the introduction of 72 mc
Read more →IRWDIronwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update Ironwood revenue in 2016 was $274 million, an 83% increase over 2015, driven primarily by 2016 LINZESS (linaclotid
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update Ironwood revenue in 2016 was $274 million, an 83% increase over 2015, driven primarily by 2016 LINZESS (linaclotide) U.S. net sales of $626 million and expansion of LINZESS commercial margin to
Read more →IRWDIronwood Pharmaceuticals Appoints Amy Schulman to Board of Directors
Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors CAMBRIDGE, Mass., January 04, 2017 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Amy Schulman to its board of directors. Schulman is an accomplished leader and entrepreneur wi
Read more →IRWDIronwood Pharmaceuticals Provides Third Quarter 2016 Investor Update Ironwood revenue increased 67% to $66 million in 3Q 2016 over 3Q 2015 Linzess (linaclotide) U.S. net sales increased 40% to $164
Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update Ironwood revenue increased 67% to $66 million in 3Q 2016 over 3Q 2015 Linzess (linaclotide) U.S. net sales increased 40% to $164 million in 3Q 2016 over 3Q 2015; net profit for the brand increased 128% to $82
Read more →IRWDIronwood Closes $150 Million Debt Refinancing - Proceeds will be used to redeem all outstanding Linaclotide PhaRMA SM 11% Notes - - Refinancing reduces cost of capital with interest rate of 8.375% -
Ironwood Closes $150 Million Debt Refinancing - Proceeds will be used to redeem all outstanding Linaclotide PhaRMASM 11% Notes - - Refinancing reduces cost of capital with interest rate of 8.375% - Transaction expected to fund in early January 2017, subject to and concurrent
Read more →IRWDIronwood Pharmaceuticals Provides Second Quarter 2016 Investor Update Ironwood revenue increased 96% to $54.4 million in 2Q 2016 compared to 2Q 2015 LINZESS (linaclotide) U.S. net sales increased 34
Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update Ironwood revenue increased 96% to $54.4 million in 2Q 2016 compared to 2Q 2015 LINZESS (linaclotide) U.S. net sales increased 34% to $150.5 million in 2Q 2016 over 2Q 2015; net profit for the brand increased
Read more →IRWDIronwood Pharmaceuticals Provides First Quarter 2016 Investor Update Progress across priority opportunities, including two Phase IIb trials underway, and lesinurad license establishes new uncontroll
Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update Progress across priority opportunities, including two Phase IIb trials underway, and lesinurad license establishes new uncontrolled gout franchise LINZESS (linaclotide) U.S. net sales increased ~44% to $137 m
Read more →IRWDIronwood Pharmaceuticals Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad - Includes FDA-approved ZURAMPIC (lesinurad), expected to launch second half 2016 for hyperuricemia assoc
Ironwood Pharmaceuticals Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad - Includes FDA-approved ZURAMPIC (lesinurad), expected to launch second half 2016 for hyperuricemia associated with uncontrolled gout, and lesinurad/allupironol fixed dose combination -
Read more →IRWDIronwood Pharmaceuticals Appoints Andrew Dreyfus to Board of Directors
Ironwood Pharmaceuticals Appoints Andrew Dreyfus to CAMBRIDGE, Mass., April 7, 2016 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the appointment of Andrew Dreyfus, president and chief executive officer of Blue Cross Blue Shield of Massachusetts, to its board of
Read more →IRWDIronwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update Key advancements within three blockbuster opportunities: IBS-C/CIC, vascular/fibrotic diseases and refractory GERD
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update Key advancements within three blockbuster opportunities: IBS-C/CIC, vascular/fibrotic diseases and refractory GERD LINZESS (linaclotide) U.S. net sales increased ~53% to $455 million in 2015; o
Read more →IRWDIronwood Pharmaceuticals Details Strategy to Build Top-Performing Commercial Biotechnology Company - At least $1 billion in LINZESS (linaclotide) annual net sales expected by 2020; greater than $2 b
Ironwood Pharmaceuticals Details Strategy to Build Top-Performing Commercial Biotechnology Company - At least $1 billion in LINZESS (linaclotide) annual net sales expected by 2020; greater than $2 billion linaclotide U.S. peak sales potential - - At least three additional bloc
Read more →IRWDIronwood Pharmaceuticals Provides Third Quarter 2015 Investor Update LINZESS (linaclotide) prescriptions increased approximately 38% to over 550 thousand in third quarter 2015 compared to third quar
Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update LINZESS (linaclotide) prescriptions increased approximately 38% to over 550 thousand in third quarter 2015 compared to third quarter 2014 LINZESS U.S. net sales increased approximately 47% to $117.5 million i
Read more →IRWDAllergan Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (U.S.) (862) 261-7558 Janet Kettels (Int l) +447738506476 Ironwood Investors: Meredith Kaya (617) 374-5082 Media: Trista Morri
NEWS RELEASE CONTACTS: Allergan Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (U.S.) (862) 261-7558 Janet Kettels (Int l) +447738506476 Ironwood Investors: Meredith Kaya (617) 374-5082 Media: Trista Morrison (6
Read more →IRWDIronwood Pharmaceuticals Provides Second Quarter 2015 Investor Update LINZESS (linaclotide) U.S. net sales of $112.1 million in second quarter 2015 Total LINZESS prescriptions increased approximatel
Ironwood Pharmaceuticals Provides Second Quarter 2015 Investor Update LINZESS (linaclotide) U.S. net sales of $112.1 million in second quarter 2015 Total LINZESS prescriptions increased approximately 56% in second quarter 2015 compared to second quarter 2014 Advanced innovati
Read more →IRWDIRONWOOD PHARMACEUTICALS PROVIDES FIRST QUARTER 2015 INVESTOR UPDATE LINZESS (linaclotide) U.S. net sales of $95.5 million in first quarter 2015 Total LINZESS prescriptions increased approximately 9
IRONWOOD PHARMACEUTICALS PROVIDES FIRST QUARTER 2015 INVESTOR UPDATE LINZESS (linaclotide) U.S. net sales of $95.5 million in first quarter 2015 Total LINZESS prescriptions increased approximately 90% in first quarter 2015 compared to first quarter 2014 Reported positive top-
Read more →IRWDIronwood Pharmaceuticals Appoints Lawrence Olanoff, M.D., Ph.D., to Board of Directors
Ironwood Pharmaceuticals Appoints Lawrence Olanoff, M.D., Ph.D., to CAMBRIDGE, Mass., April 16, 2015 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the appointment of Lawrence Olanoff, M.D., Ph.D., to its board of directors as well as to its pharmaceutical advisor
Read more →IRWDIRONWOOD PHARMACEUTICALS PROVIDES FOURTH QUARTER 2014 INVESTOR UPDATE U.S. LINZESS (linaclotide) quarterly total prescription growth of approximately 12% versus prior quarter and approximately 108%
IRONWOOD PHARMACEUTICALS PROVIDES FOURTH QUARTER 2014 INVESTOR UPDATE U.S. LINZESS (linaclotide) quarterly total prescription growth of approximately 12% versus prior quarter and approximately 108% versus prior year LINZESS net sales of $93.8 million in fourth quarter; $297.0
Read more →IRWDIRONWOOD PHARMACEUTICALS PROVIDES THIRD QUARTER 2014 INVESTOR UPDATE Strong LINZESS (linaclotide) demand: total prescription growth of 22% and sequential U.S. net product sales growth of 27% Four mi
IRONWOOD PHARMACEUTICALS PROVIDES THIRD QUARTER 2014 INVESTOR UPDATE Strong LINZESS (linaclotide) demand: total prescription growth of 22% and sequential U.S. net product sales growth of 27% Four mid- to late-stage linaclotide clinical trials expected by year end 2014 Enrollm
Read more →IRWDIRONWOOD APPOINTS TWO NEW SENIOR EXECUTIVES TO SUPPORT CONTINUED GROWTH AS A LEADER IN GASTROENTEROLOGY Chief Financial Officer and Senior Vice President of Finance and Corporate Strategy Senior Vic
IRONWOOD APPOINTS TWO NEW SENIOR EXECUTIVES TO SUPPORT CONTINUED GROWTH AS A LEADER IN GASTROENTEROLOGY Chief Financial Officer and Senior Vice President of Finance and Corporate Strategy Senior Vice President of Corporate Communications CAMBRIDGE, Mass., September 2, 2014 Iro
Read more →IRWDIRONWOOD PHARMACEUTICALS PROVIDES SECOND QUARTER 2014 INVESTOR UPDATE 36% growth in total LINZESS (linaclotide) prescriptions quarter over quarter Second quarter LINZESS U.S. net product sales of $6
IRONWOOD PHARMACEUTICALS PROVIDES SECOND QUARTER 2014 INVESTOR UPDATE 36% growth in total LINZESS (linaclotide) prescriptions quarter over quarter Second quarter LINZESS U.S. net product sales of $62.7 million CAMBRIDGE, Mass., August 4, 2014 Ironwood Pharmaceuticals, Inc. (N
Read more →Competitive Position
How IRWD ranks across every disease it competes inCompetitive Position is a premium feature
See how IRWD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial